Significance of miR-1290 in glioblastoma patients with epilepsy

Epilepsy is often the initial symptom in two-thirds of glioblastoma (GBM) patients. Existing studies have shown that microRNAs (miRNAs) play a crucial role in epilepsy. However, their role in epilepsy associated with glioblastoma remains unclear. The aim of our study was to investigate the correlation between miR-1290 expression in GBM patients and pre-operative seizures, as well as patient outcomes. 81 GBM patients were enrolled in our study, and an independent validation was carried out with 92 similar cases. MiRNA profiling of the 81 patients was conducted to identify differentially expressed miRNAs. In the validation cohort, key miRNAs were validated by using quantitative reverse transcriptase polymerase chain reaction (q-PCR). Additionally, functional analysis of these miRNAs was performed through Gene Ontology (GO) analysis. Our array analysis disclosed that there were seven under-expressed miRNAs in patients with preoperative seizures when compared to those without preoperative seizures. Among them, miR-1290 showed the highest fold change. Validation in an independent cohort verified that patients with favorable seizure outcomes had higher miR-1290 expression levels. Functional enrichment analysis demonstrated that the gene expression profiles associated with miR-1290 were enriched in biological processes related to transcription and cell cycle regulation, especially the functions mediated by RNA polymerase II. MiR-1290 emerges as a promising biomarker for predicting seizure susceptibility and overall survival in GBM patients. A specific evaluation of miR-1290 may lead to targeted diagnostic and therapeutic interventions, potentially providing novel strategies for enhancing patient outcomes.